Effects of Cerebrolysin™ on amyloid-β deposition in a transgenic model of Alzheimer’s disease
We investigated the potential mechanisms through which Cerebrolysin™, a neuroprotective noothropic agent, might affect Alzheimer’s disease pathology. Transgenic (tg) mice expressing mutant human (h) amyloid precursor protein 751 (APP751) cDNA under the Thy-1 promoter (mThyl-hAPP751) were treated for four weeks with this compound and analyzed by confocal microscopy to asses its effects on amyloid plaque formation and neurodegeneration. In this model, amyloid plaques in the brain are found much earlier (beginning at 3 months) than in other tg models. Quantitative computer-aided analysis with anti-amyloid-β protein (Aβ) antibodies, revealed that Cerebrolysin significantly reduced the amyloid burden in the frontal cortex of 5-month-old mice. Furthermore, Cerebrolysin treatment reduced the levels of Aβ1–42. This was accompanied by amelioration of the synaptic alterations in the frontal cortex of mThyl-hAPP751 tg mice. In conclusion, the present study supports the possibility that Cerebrolysin might have neuroprotective effects by decreasing the production of Af and reducing amyloid deposition.
KeywordsFrontal Cortex Alzheimer Disease Amyloid Precursor Protein Nontg Mouse Synaptophysin Immunoreactivity
Unable to display preview. Download preview PDF.
- Brown DF, Risser RC, Bigio EH, Tripp P, Stiegler A, Welch E, Eagan KP, Hladik CL, White CL (1998) Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 57: 955–960PubMedCrossRefGoogle Scholar
- Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E, the HNRC Group (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol 9: 209–217Google Scholar
- Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemes J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523–527PubMedCrossRefGoogle Scholar
- Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Guiffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Williamson R, Rossor M, Owen M, Hardy J (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349: 704PubMedCrossRefGoogle Scholar
- Martin LJ, Cork LC, Koo EH, Sisodia SS, Weidemann A, Beyreuther K, Masters C, Price DL (1989) Localization of amyloid precursor protein (APP) in brains of young and aged monkeys. Soc Neurosci Abstr 15: 23Google Scholar
- Masliah E, Rockenstein E (2000) Genetically altered transgenic models of Alzheimer’s disease. J Neural Transm [Suppl] 59: 175–183Google Scholar
- Masliah E, Terry RD, Alford M, DeTeresa RM, Hansen LA (1991b) Cortical and subcortical patterns of synaptophysin-like immunoreactivity in Alzheimer disease. Am J Pathol 138: 235–246Google Scholar
- Masliah E, Mallory M, Alford M, DeTeresa R, Iwai A, Saitoh T (1997) Molecular mechanisms of synaptic disconnection in Alzheimer’s disease. In: Hyman BT, Duyckaerts C, Christen Y (eds) Connections, cognition and Alzheimer’s disease, Springer, Berlin Heidelberg New York Tokyo, pp 121–140CrossRefGoogle Scholar
- Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of Abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20: 4050–4058PubMedGoogle Scholar
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177PubMedCrossRefGoogle Scholar
- Terry RD, Hansen L, Masliah E (1994) Structural basis of the cognitive alterations in Alzheimer disease. In: Terry RD, Katzman R (eds) Alzheimer disease. Raven Press, New York, pp 179–196Google Scholar
- Veinbergs I, Mante M, Mallory M, Masliah E (2000) Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm 59: 273–280Google Scholar